drugset / Trial / NCT06207175
A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine
Phase 3
Unknown
1260 enrolled
Beijing Health Guard Biotechnology, Inc
Dr. M Djamil Hospital, Padang · collabUniversity of Muhammadiyah Malang Hospital · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
This Study to Evaluate the Immunogenicity and Safety of Candidate Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli) Administered Intramuscularly in Healthy Female Participants Aged 18 to 45 Years
Timeline
- Start
- 2023-11-21
- Primary completion
- 2024-11-17
- Completion
- 2026-01-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Gardasil 9 | Vaccine | 0.5 ml | Intramuscular |
| Subject | Nonavalent HPV study vaccine | Vaccine | 0.5 ml | Intramuscular |